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Abstract: Chagas disease must be treated in all its stages: acute, indeterminate, chronic, and initial 
and middle determinant chronic, due to the fact that DNA of the parasite can be demonstrated by 
PCR in chronic cases, where optical microscopy does not detect parasites. Nifurtimox (NF) and 
benznidazole (BNZ) are the drugs accepted to treat humans based upon ethical considerations 
and efficiency. However, both the drugs produce secondary effects in 30% of the cases, and the 
treatment must be given for at least 30–60 days. Other useful drugs are itraconazole and posacon-
azole. The latter may be the drug to treat Chagas disease in the future when all the investigations 
related to it are finished. At present, there is no criterion of cure for chronic cases since in the 
majority, the serology remains positive, although it may decrease. In acute cases, 70% cure with 
NF and 75% with BNZ is achieved. In congenital cases, 100% cure is obtained if the treatment 
is performed during the first year of life. In chronic acquired cases, 20% cure and 50% improve-
ment of the electrocardiographic changes are obtained with itraconazole.
Keywords: Chagas disease, treatment, nifurtimox, benznidazole, allopurinol, itraconazole, 
posaconazole
Introduction
Recently, we have celebrated the centenary of the discovery of Chagas disease by the 
distinguished Brazilian investigator, Dr Carlos Chagas (1909–2009).1
Although we know that Chagas disease has existed for more than 9000 years by the 
demonstration of Trypanosoma cruzi in remains of mummies off the coast of southern 
Peru and northern Chile belonging to the Chinchorro culture (7000 BC to 1500 AD),2 
its etiological treatment is recent, dating from the decade 1970 to1980 when nifurtimox 
(NF) and benznidazole (BNZ) were applied based on an empirical therapy.3–5
There are several drugs which act in vitro on T. cruzi, in cultures of epimastigotes and 
trypomastigotes, in tissue cultures of amastigote forms, and in vivo in different species of 
infected animals with diverse strains (subpopulations) of the parasite. It is important to 
point out that the drugs which are used in Chagas disease therapy must have an effect on 
the intracellular amastigote forms, which are the reproductive forms in the vertebrate host. 
The epimastigote and trypomastigote forms of these hosts derive from the amastigotes, 
and for this reason, their response to different drugs has less importance.6,7
A rational therapy for T. cruzi should be based on the following:
1.  Inhibitors of trypanothione metabolism
2.  Inhibitors of cysteine protease
3.  Inhibitors of phospholipidsDrug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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4.  Inhibitors of pyrophosphate metabolism
5.  Drugs which inhibit protein or purine synthesis
6.  Inhibitors of ergosterol
7.  Natural drugs
inhibitors of trypanothione metabolism
Trypanothione (N1, N8-bisglutatyonilspermidine) and 
  trypanothione reductase are unique systems in the   kinetoplastid 
protozoa, which replace intracellular   glutathione and 
  glutathione reductase, the principal mechanism of the thyol-
redux system. Although trypanothione reductase is an essen-
tial enzyme in Leishmania donovani and Leishmania mayor, 
the overexpression of the enzyme in L. donovani and L. mayor 
does not alter its sensitivity in vitro to agents that induce 
oxidative stress such as NF, nitrofurazone, and gentian violet. 
Inhibitors of trypanothione metabolism such as buthionine 
sulfoximine (BSO) are ideal potential   candidates as drugs 
against T. cruzi; alone or jointly with free   radical-producing 
drugs such as NF and BNZ8 (Figure 1).
Cysteine protease inhibitors (CPi)
Cruzipain (cruzain, gp 51/57) is a simile of cathepsin 
L-cysteine protease responsible for the proteolytic activity 
in all the life stages of T. cruzi. The genes that code for this 
protein have been cloned and expressed. A recombinant 
enzyme has been elaborated, and different drugs have been 
studied which inhibit specifically the CPI protease in vitro, 
blocking the proliferation of epimastigotes and amastigotes 
and arresting metacyclogenesis. It has been demonstrated 
that these drugs block the development of cruzipain and its 
transport by lysosomes. These facts indicate that cruzipain 
is an ideal target; however, to date, although CPI has been 
applied in murine models with acute and chronic infection, 
obtaining parasitological cure with minimal toxicity, the 
short half-life of the drug, which requires high and increasing 
doses, inhibits its use in clinical practice.9
inhibitors of phospholipids
Alkyl-lysophospholipids (ALP) are synthetic analogs of 
  lysophospholipids, which have been shown to be   effective 
in vitro and in vivo on T. cruzi and trypanosomatides. 
  Miltefosine, one of its representatives, has been used orally 
in visceral leishmaniasis with good results. ALP selectively 
blocks the biosynthesis of phosphatydilcoline (PC) of T. cruzi 
through the transmethylation of the Greenberg pathway, in 
contrast to the vertebrate host where the Kennedy pathway 
of CDP choline is predominant.10 However, it is necessary to 
assess its clinical efficacy in Chagas disease because milte-
fosine is teratogenic, and congenital transmission of T. cruzi 
is actually a real problem.
inhibitors of pyrophosphate metabolism
The inorganic pyrophosphates (P2O7
4−; PPi) and other short 
chain, tri and tetra, polyphosphates are those which have the 
greatest energy of phosphate compounds in trypanosomatides 
(T. cruzi, Trypanosoma brucei, and Leishmania mexicana) and 
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Figure 1 Biosynthesis of glutathione and trypanothione in T. cruzi: Glutathione is synthesized by the consecutive action of γ-glutamylcysteine synthetase and glutathione 
synthetase in an ATP-dependent reaction. in T. cruzi, two molecules of glutathione are conjugated with spermidine to synthesize trypanothione (N1, N8-bisglutathionylspermidine, 
T(SH)2). The host is unable to synthesize T(SH)2. γ-Glutamylcysteine synthetase is the step-limiting enzyme in this process and can be inhibited by BSO.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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apicomplexa parasites (Toxoplasma gondii). They have 10–15 
times more energy than ATP. PPi is distributed throughout the 
cell but is concentrated in the acidocalcisomes, specialized 
acid vacuoles with large quantities of Ca+ +. PPi enzymes of T. 
cruzi, such as a proton-translocating pyrophosphatase in aci-
docalcisomes and pyruvate phosphate dikinase in glycosomes, 
suggest that PPi has an important role in parasite survival. 
This has been confirmed by the observation that pamidronate, 
alendronate, and risedronate, which contain biphosphonates, 
nonmetabolizable pyrophosphate analogs currently used in 
human medicine in alterations of bone reabsorption, selec-
tively inhibit the proliferation of intracellular amastigotes 
and tachyzoites of T. gondii. It has been demonstrated that 
risedronate (Ris) acts in vitro on epimastigotes and cell cul-
tures of amastigotes of T. cruzi and also reduces the infection 
in mice with acute infection, eliminating almost completely 
the parasitemia and intracellular amastigote forms. This drug 
inhibits the farnesyl pyrophosphate synthase of the parasite, 
blocking the biosynthesis of poly-isoprenoids.11 One inhibitor 
of farnesyltransferase, tipifarnib (R 115777), which inhibits 
cytochrome P450 sterol demethylase (CYP51), is a potential 
target against T. cruzi, but in spite of its success in experimen-
tal animals, it has not been applied in humans.12
The sterol 14 demethylase of T. cruzi has been studied 
(TCCYP51). It is related catalytically to the CYP51 of   animal 
fungi.13 Inhibition by obtusifoliol and its analogs reduce enzyme 
activity enormously. TCCYP51 constitutes a potential target 
against T. cruzi; however, to date, no experimental   surveys had 
been performed to establish its efficacy in animals.
Most of the inhibitors of pyrophosphate metabolism, 
which contain bisphosphonates, are associated to long-term 
bone necrosis. These serious side effects in humans discard 
them as potential candidates for therapy.
Drugs which inhibit protein  
or purine synthesis
Allopurinol
T. cruzi cannot synthesize purines de novo as humans do. 
Allopurinol, 4-hydroxypirazole(3,4-d)pyrimidine (HPP), is 
an analog of hypoxanthine, which decreases uric acid and the 
conversion of hypoxanthine to xanthine. For this reason, it is 
used to treat gout, which is characterized by the deposit of 
uric acid in the joints. HPP inhibits the   epimastigote forms 
in culture. In mice infected with T. cruzi and treated with 
allopurinol, an important reduction of the parasitemia is 
obtained, although some parasite strains are resistant to the 
drug.14 T. cruzi changes HPP to APP (4 aminopyrazolo(3,4-d)
pyrimidine), which is 15 times more powerful against 
  epimastigotes than HPP. If APP is   administered to mice 
infected with T. cruzi, a suppression of the parasitemia is 
obtained with a dose 400 times lower than allopurinol.15 
In patients with acute Chagas disease treated with allopurinol 
at high doses (20–30 mg/day) for 60 days, no reduction of 
the parasite burden was obtained. In a multinational study 
performed in Argentina, Brazil, and Bolivia in patients with 
chronic Chagas disease treated with 900 mg/day for 60 days, 
no parasitological cure was obtained. This drug was well 
tolerated in a number of studies performed in patients with 
chronic Chagas disease, and in some of these, an improve-
ment of the electrocardiographic alterations in chronic Cha-
gas cardiopathy (CCC) was demonstrated.16,17 It has been used 
in heart transplants in Chagas patients with good results.18 
In exceptional cases, it has been necessary to suspend the 
treatment due to its secondary effects.17
inhibitors of ergosterol
Diverse azolic products have been used with success in human 
and veterinary medicine. These drugs interface in sterol 
  synthesis and, together with other heterocyclic nitrogenated 
compounds, belong to the group of drugs which inhibit ergos-
terol synthesis. T. cruzi has ergosterol; the antimycotic prevents 
its synthesis without affecting the human host, who has cho-
lesterol. Cholesterol differs from ergosterol by the presence 
of a 24 methyl group and double bonds in 7A and 22A. The 
enzymes which produce the methylation and the double bonds 
of ergosterol do not have counterparts in mammalian choles-
terol synthesis. Several of these azolic products have been 
studied for Chagas disease treatment: miconazole, econazole, 
ketoconazole, itraconazole, fluconazole, and posaconazole 
(Figure 2). With these drugs, a parasitological cure has been 
obtained in mice with acute and chronic Chagas disease.19 
Ketoconazole, itraconazole, and DO 870 inhibit cytochrome 
P450-dependent lanosterol C14 demethylase, thus reducing 
ergosterol synthesis. Although mammals have this enzyme, 
it is much less sensitive to the drugs than those of fungi or 
of T. cruzi. Itraconazole has been applied in the treatment of 
chronic indeterminate Chagas disease and CCC, based on the 
results of the drug in experimental investigations.20
The absolute oral bioavailability of itraconazole was 55% 
after a single 100-mg capsule was taken by six volunteers. 
The bioavailability was maximal when the capsules were 
taken with a full meal.
The drug prevents cardiopathy, compared to controls 
  without therapy, and improves 50% of the   electrocardiographic 
alterations of patients with CCC. Twenty percent of these cases 
are ‘cured’ of parasites, determined by   xenodiagnosis, PCR in Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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blood, hybridization probes in blood, PCR in   dejections, and 
hybridization probes in dejections of   triatomines applied to 
these patients.21 However, none of the ‘cured’ cases presented 
a negative conventional serology (indirect hemagglutination 
(IHA), indirect immunofluorescence (IF), or ELISA) for T. 
cruzi.17 When the drug DO 870 was administered to mice 
with acute infection (105 T. cruzi Y strain), the treated animals 
lived longer than the controls without treatment or those 
treated with NF or ketoconazole; 105 days survival versus 
21. A 60% cure was obtained, which was judged by control of 
parasitemia, hemocultures, and PCR. When this therapy was 
applied to mice with chronic infection (104 T. cruzi Bertoldo 
strain), after 40–50 days, 50% of the controls survived and 
30% of these had negative PCR, whereas the parasitologi-
cal cure was 80%–90% in the treated group.19 Today, DO 
870 has been discontinued because of its cardiotoxicity, 
but posaconazole (SCH 56592), BMS-207, 147 (ravucon-
azole), VR-9825, and TAK-187 have demonstrated activity 
against T. cruzi in vitro and in vivo. Of these compounds, 
posaconazole has proved to be efficient and with very good 
tolerance in studies performed in patients with oropharyn-
geal candidiasis.22 It has been observed that the majority of 
these compounds (posaconazole, ravuconazole, VR-9825, 
and TAK-187) have activity against T. cruzi strains partially 
resistant to NF, BNZ, and in which ketaconazole does not 
function.10 Posaconazol with amiodarona, an antiarrhythmic 
drug, has a synergistic activity against T. cruzi in vitro and 
in vivo.23 Recently, success was demonstrated with posacon-
azole in a patient with chronic Chagas disease and systemic 
lupus erythematosus. This patient was previously treated with 
BNZ with reduction of the parasitemia but not elimination of 
T. cruzi.24 Posaconazole maximal absorption, Tmax, is approxi-
mately 3–5 h. Steady-state plasma concentrations are reached 
in 7–10 days. Vd is 1774 L, suggesting extensive extravascular 
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distribution and penetration into body tissues. Over 98% of 
the drug is bound, protein primary to albumin.
Its metabolism involves glucuronide conjugation via 
uridine diphosphate glucuronidation. Its elimination is 
approximately 71% in feces and 13% in urine in up to 120 h. 
The mean t½ is 35 h.
Natural drugs
A great spectrum natural of products has been used against 
T. cruzi, but very few are useful at a concentration of 
10 µg/mL, considering that the IC50 for NF and BNZ is less 
than 3 µg/mL. Some products block the respiratory chain 
of the parasite, such as boldo (Peumus boldus) alkaloids 
and   naphthoquinone extracted from Calceolaria sessilis.25 
Other alkaloids extracted from Brazilian plants which have 
  isoquinoline have an effect on T. cruzi.26 Some natural drugs 
inhibit the response of T. cruzi to oxidative stress by producing 
superoxide radicals.8 The triterpenes of   Arrabidaea triplin-
ervia and their derivatives, such as diterpenes, komaroviqui-
none, and terpenoids isolated from Pinus oocarpa, have action 
on epimastigotes and trypomastigotes of T. cruzi.27–29 In the 
majority of the natural drugs, the exact mechanism of action 
is not known. The great majority of them have effects on 
epimastigote forms and some on culture amastigotes. Very 
few have been used in experimental studies in murines, and 
none have been used in clinical surveys. To date, no natural 
product which acts on T. cruzi transialidase has been studied, 
although this enzyme is an optimal target. Only one natural 
drug has been used on CPI, inhibiting cruzipain synthesis; this 
product is a 164-residue amino acid protein extracted from 
seeds of Bauhinia bauhinioides. No experimental investiga-
tions have been performed with this product.30
Treatment of human infection
Chagas disease has regional characteristics. In Brazil, acha-
lasia of the esophagus is more frequent than megacolon, 
whereas in Chile, it is the opposite. Acute acquired clinical 
cases are frequent in the Chaco region of Argentina, Paraguay, 
and Bolivia but are infrequent in Chile.31
Treatment with NF and BNZ began in the 1970s 
and is based on an empirical treatment.32–34 NF is 4-([5-
nitrofurfuryledene]amino)-3-methylthiomorpholine-1,1 
dioxide (Figure 3). It acts by the production of free radicals, 
superoxide anions, hydrogen peroxide, and electrophilic 
metabolites.35 It has been demonstrated that in addition to 
the metabolic action of the drug on T. cruzi, its   incorporation 
and transport by the parasite is of great importance. There are 
strains with some resistance to NF, which differ due to a 
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lower intake and transportation of the drug, rather than by 
the amount of free radical production. T. cruzi, in the pres-
ence of NF, increases oxygen consumption and H2O2 and 
superoxide radical production.
The drug BNZ (N-benzyl-2-nitroimidazole-1-acetamide) 
was introduced for human clinical use in 1978. The drug 
inhibits protein synthesis, originating a degradation of 
macromolecule biosynthesis. Reduced metabolites of BNZ 
in covalent unions with macromolecules interact with the 
DNA of the parasite.8 The drug inhibits the respiratory chain. 
The free radical production is lower than with NF. Figure 3 
describes the mechanisms of action of NF and BNZ. Both 
drugs produce important collateral effects, especially in 
adults, because newborn, nursing, and small children toler-
ate the drugs better.36 The secondary effects of NF and BNZ 
are described in Table 1. Based on this information, we will 
discuss the treatment of human Chagas disease in its different 
stages with the drugs currently in use.
Current drug therapy
Some investigators believe that Chagas disease must be treated 
only in acute (acquired or congenital) or chronic reactivated 
cases (by immunosuppression diseases like AIDS; other 
immune depression diseases, iatrogenic immune depression, 
like transplants, etc). They do not agree to treat chronic indeter-
minate or determinate cases based on the fact that the pathology 
is originated by an autoimmune process.37–40   Nevertheless, the 
other group of scientific   investigators believe that the treatment 
of chronic Chagas disease is important, based on the observa-
tion of DNA of T. cruzi by PCR in cases where optical and 
election microscopy do not.41,42 It is difficult to sustain that this 
finding corresponds to DNA of death parasites because it has 
been detected in many cases with several decades of evolu-
tion.42,43 It has been demonstrated that there is a correlation 
between the antigen burden and/or DNA of the parasite with 
the intensity of the pathological processes (inflammation, cel-
lular damage) in experimental animal surveys and in humans 
with chronic infection.44–46 There are no investigations which 
directly demonstrate the vitality of the parasites in chronic 
Chagasic patients, but there are investigations that indicate 
the utility of the treatment.47–53
Furthermore, OPS–WHO and a group of experts on 
  Chagas disease patronize treatment in acute and initial middle 
chronic cases.54 To determinate the utility of BNZ in the treat-
ment of CCC, a multinational survey is been performed, the 
Benefit Project. In a pilot survey double-blind of 600 cases, 
300 CCC received BNZ 5 mg/kg during 60 days and 300 
placebo. The second group included 6000 patients, 3000 with 
BNZ and 3000 with placebo. It is expected that in 2012–2013, 
the investigation will be finished.55,56 Recently, it has been 
demonstrated that in patients with CCC, the antibodies 
against T. cruzi only react with antigens of the parasite and 
not with the antigens from the host.57 These investigations 
and others which demonstrate that there is no correlation 
between the intensity of the autoimmune processes (when 
they appear) and the magnitude of the damage in chronic 
Chagas disease43 are against the autoimmune theory.
Acute cases
Patients with clinical manifestations must receive treatment: 
those with an infection of less than 4 months, as well as the 
acute cases with easy detection of parasites in fresh samples 
and smears and with positive conventional serology (IHA, 
complement fixation (CF), IF, ELISA, and immunoblotting 
(IB) with positive IgM). The ideal is to treat these cases with 
NF 8 mg/kg/day for 30–60 days in adults and 10 mg/kg/day 
for the same period in children. This daily quantity must be 
divided into three doses taken after meals (every 8 h). In 
Brazil, where NF does not exist, BNZ is used: 5 mg/kg/day 
for 60 days in adults and 5–10 mg/kg/day (7.5 mg/kg/day) for 
60 days in children divided into two or three doses (every 12 
or 8 h) after meals. In an investigation performed in Santiago 
del Estero (Argentina) with 470 cases, the majority of the 
children (84.4%) aged 1–9 years with acute Chagas disease 
who presented an ophthalmic lymph node complex, 367 were 
treated with 25 mg/kg of NF for 15 days   continuing with 
15 mg/kg for another 77 days, whereas 40 received placebo 
and another 20 other anti-Chagasic drugs. The drug tolerance 
was greater in small children, and the dose of 15 mg was bet-
Table 1 Adverse reactions to nifurtimox and benznidazole
Digestive alterations
Loss of weight
Gastric upset
Nausea
vomiting
Hematological alterations (by hypersensitivity)
Leukopenia
Thrombocytopenia
Agranulocytosis
Dermatological alterations
erythematous, light-sensitive rash
Atopic dermatitis (mild or severe)
Occasionally, Stevens–Johnson syndrome, which requires the suspension 
of therapy
Neurological alterations
Polyneuropathy, dose dependent. in general, it appears in schedules of 
high dose. in the usual dose of 5 mg/kg/day of benznidazole, 10%–30% of 
the patients present neuropathies, especially at the end of treatment.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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ter tolerated than that of 25 mg. After 60 days of treatment, 
the direct parasitological tests were negative in both the 
groups who received therapy; however, in the placebo group, 
there were 28.6% positive cases. After 18 months, there was 
69% seroconversion of the treated patients; in other words, 
they passed from positive to negative. However, the placebo 
group maintained positive serology, IHA, CF, and IF.58 With 
BNZ in acute acquired cases, 76% cure is obtained.59
Congenital infection
Treatment must commence as soon as the diagnosis is 
performed, in other words, when the clinical suspicion 
is confirmed by observation of the parasite in fresh samples 
of blood smears, microstrout, etc. Sometimes the diagnosis 
is confirmed when the child is in the chronic period (8 or 
more months) by persistent positive serology after this period. 
Better therapeutic results are obtained when the diagnosis is 
more precocious. It is important to perform a clinical, sero-
logical, and parasitological follow-up of the treated newborn. 
Recently, the utility of PCR in the precocious diagnosis of 
congenital Chagas disease in neonates has been confirmed; 
its effectiveness is greater than that of xenodiagnosis.60,61 This 
technique has great utility as has been demonstrated by Para-
guayan investigators and others in the follow-up of treated 
cases. Thus, for example, in an investigation performed in the 
maternity ward of the Clinical Hospital of Asunción and in 
the Regional Hospital of San Pedro, Paraguay, the newborn 
of Chagasic mothers were studied. Three percent were posi-
tive by microscopy, which increased to 10% when they added 
the cases with persistent positive serology at 6 months. Out 
of 58 newborn, in two cases, T. cruzi was observed at birth 
and four presented positive PCR with negative microscopic 
investigation. All the positive cases were treated with BNZ 
and followed for four years by conventional serology and 
PCR. In another study performed in an endemic area of Para-
guay of 1865 neonates with Chagasic mothers, in 104 cases, 
congenital infection was demonstrated by direct microscopic 
observation, PCR, and serology; ELISA, ELISA AIDS, and 
IF. PCR was the most sensitive test.62
All congenital cases must be treated since up to 98% 
of such treatments may produce negative serology and 
parasitemia; the earlier the treatment is begun, the better 
the response obtained. NF must be administered in doses 
of 8–10 mg/kg/day for 60 days, taken every 8 or 12 h, or 
BNZ 5–7 mg/kg/day for 60 days. To avoid secondary effects 
(convulsions), it is recommended to associate phenobarbital 
in therapeutic doses during the first 15 days of treatment. In 
case of secondary dermatological reactions, it is suggested 
to add antihistaminics. Adverse reactions in neonates are 
fewer than in adults.
It is important to perform a precocious diagnosis of con-
genital cases to treat them opportunely. For this purpose, the 
following is suggested in pregnant women and newborn.
Pregnant women
Serological test jointly with other tests such as VDRL dur-
ing the first trimester of pregnancy and follow-up of the 
positive cases, until the diagnosis of congenital infection is 
confirmed or discarded. This activity must be performed in 
all women of fertile age, in pregnant women from endemic 
areas, and in women with a history of having lived in 
these zones.
Newborn
Serological study for T. cruzi infection, together with VDRL 
and other tests. In the positive cases, a follow-up must be 
realized until the diagnosis is confirmed or discarded.
Accidental Chagas disease
All accidental cases must be treated with the same drugs as 
the acute infections acquired from the vector for 15 days. 
In this group, the transfusion by error from a Chagasic donor 
must be considered. In persons who work in laboratories and 
have a puncture accident with contaminated samples with 
infective T. cruzi forms, the confirmation of the contamina-
tion of the object with the parasite and the posterior infection 
of the patient (serology and PCR) must be performed. If there 
are positive results, immediate treatment must be undertaken 
with BNZ 7–10 mg/kg/day for 15 days, depending on the 
immunological state of the person. A serological study must 
be done at 15–30 and 60 days.
Organ transplants
A transplant in which the donor or recipient has Chagas dis-
ease must always be treated, with NF 8 mg/kg/day in adults, 
10 mg/kg/day in children for 60 days, or BNZ 5 mg/kg/day 
in adults and 5–8 mg/kg/day in children for 60 days. In bone 
marrow transplants with T. cruzi infections (which receive it 
in 40% of the cases), the treatment must be maintained for 
2 years, and in solid organ receptors, treatment must be given 
for the period in which immunosuppressors with insufficient 
CD4 lymphocytes for an adequate immune response are used. 
In these patients, the most commonly prescribed drugs are 
the traditional NF and BNZ. In the model of patients exposed 
by organ transplant, a number of situations may be produced, 
such as primoinfections and reactivations; thus, it is important Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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to perform a good screening of donor and recipient before 
the transplant. The clinical manifestations of reactivation 
usually differ from that of the acute phase (primoinfection); 
for this reason, the monitoring of patients after the transplant 
is relevant. In both situations, the receptor who receives an 
organ from a Chagasic donor or a Chagasic reactivated recep-
tor must be treated with NF or BNZ.
Reactivations of chronic Chagas 
disease and treatment of Chagas 
disease in immunosuppressed 
patients
Patients with chronic Chagas disease who acquire AIDS 
or in whom immunosuppressor therapy is administered 
must receive treatment at the same dose as the group men-
tioned above for 5 or more months. In these cases, the most 
suitable strategy is prevention, performing serology for 
Chagas disease in all AIDS patients. In the primoinfection 
by T. cruzi in AIDS patients, the same treatment schedule 
must be prescribed as in reactivations, in other words, the 
same classic antiparasitic drugs are used in the standard 
doses until the immune response of the host is reconstituted 
(in some cases 60 or more days). Once the alteration of 
the immune system is normalized, including the relation 
CD4/CD8, the antiparasitic schedule is changed to every 
3 days, balancing the parasiticide effects with the adverse 
effects. AIDS patients without retroviral treatment are 
the most severely affected. In them, once the CD4 levels 
are normalized with specific antiviral treatment, maintenance 
schedules may be used.
Evaluation and follow-up  
of specific therapy
The principal objection to the treatment of Chagas disease is 
its long duration. The treatment must be maintained at least 
for 60 days, and the cure criteria depend on several factors.63,51 
Some authors consider serological conversion as necessary, 
but this sometimes happens 20 years or more after the end of 
treatment of chronic Chagas disease, and there are cases in 
which former patients die without seroconversion. Recently, it 
has been published that in treated cured mice experimentally 
infected with T. cruzi, in which no parasites and no T. cruzi 
antigens could be demonstrated, CD8 central memory cells 
maintain a positive serology for more than a year.64 We do 
not know if this process occurs in man, but if it does, we 
could explain why a cure in chronic cases may be reached 
without seroconversion.
Others consider the following parameters as cure criteria 
of the chronic period: the conversion of the xenodiagnosis 
from positive to negative, conversion of qualitative PCR 
from positive to negative, and in cardiopathies, the elimina-
tion of the electrocardiographic alterations. These changes 
must always be permanent and must persist for at least 12 
or more years independently of the conventional serologi-
cal results. There must be at least two parasitological and 
one or more clinical parameters to confirm the cure.17 In the 
acute indeterminate and determinate chronic periods, a 
follow-up must be performed with hemocultures, quantita-
tive PCR for T. cruzi, hemogram, biochemical profile, and/or 
xenodiagnosis.65,66 It must be kept in mind that serological 
tests in severe immunosuppressed patients usually have 
negative results and for this reason don’t serve to follow 
up the treatment. A prolonged persistent negativity of PCR 
with the mentioned characteristics for T. cruzi is considered 
as a cure criterion. Some authors give value to the disap-
pearance of lytic antibodies as a complement to improve 
the criterion.
Resistance of T. cruzi to drugs
in vitro and in vivo
It has been demonstrated that certain T. cruzi strains are 
resistant to NF and BNZ. This is valid especially for T. cruzi 
clones isolated from wild animals or vectors. It is important to 
emphasize that we do not know if what we observe in murine 
models happens in man. Furthermore, in many publications, 
the strains of T. cruzi have not been well characterized by 
isozymes (zymodemes), nuclear restriction enzymes (schizo-
demes), genetic composition, etc.67 No consensus exists on 
the relation of the sensitive or resistant strains and virulence.68 
Some investigators have claimed that there is a relation, in 
other words, the resistant strains are more virulent, while 
others did not find this association.69 In relation to the genetic 
composition of T. cruzi and resistance to drugs, it has been 
demonstrated in vitro that a relation exists between genetic 
distances and biological differences; among the latter, the 
resistance to NF and BNZ. This is true for epimastigotes 
and amastigotes. Trypomastigotes are the exception since in 
them, a relation between genetic distance and sensitivity to 
drugs does not exist. It is necessary to have better genotypic 
studies of T. cruzi in relation to resistance to drugs. Recently, 
it has been demonstrated that patients with chronic Chagas 
disease treated with itraconazole or allopurinol who did not 
respond to the specific therapy (there was no parasitological 
cure) were infected with the TCI lineage of T. cruzi, whereas 
those who responded to the therapy with itraconazole had Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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the lineage TCIIb, suggesting that TCI is resistant to these 
drugs and TCIIb is sensitive.70
Critical comments
At present, there is no effective therapy for the majority of 
the patients who have chronic Chagas disease in the indeter-
minate (70%–80%) and determinate (10%–20%) periods. In 
the acquired acute period, 70% of the cases are cured, and in 
newborn and nursing children with congenital Chagas disease, 
98%–100% cure is obtained. In the chronic acquired cases, 
cures reach 20% and improvement of cardiopathy 50% (with 
itraconazole). New drugs are needed with high efficacy and 
without secondary effects, especially to treat chronic cases. In 
the last few years, only posaconazole has been developed against 
human T. cruzi infection. This is due to the lack of interest of the 
international drug companies to develop new drugs with low 
returns. The people with Chagas disease have low economic 
resources. Chagas disease is one of ‘neglected diseases,’ and 
for this reason, the pharmaceutical companies do not show 
much interest. How will chronic Chagasic patients be treated if 
no new drugs are produced? They may have to be treated with 
itraconazole or posaconazole until better drugs are found.
Future investigations
In the near future, we believe that the etiological treatment of 
Chagas disease will include combination of drugs to obtain 
more efficiency and less secondary effects, eg, NF and BSO. 
Experimental studies in vitro and in vivo have demonstrated the 
synergism of these two drugs.8 Human investigations are needed to 
confirm these results. The same results could be expected with the 
association of BNZ and allopurinol or BNZ and posaconazole.
Other investigations with inhibitors of methylcarboxi-
peptidases of T. cruzi (an enzyme which doesn’t exist in 
humans) are needed because its use could represent an effec-
tive therapy against Chagas disease.
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